<![CDATA[fenomena fluktuasinya laba, total aset dan ekuitas setiap tahunnya pada perusahaan sektor farmasi BUMN dan BUMS akan berdampak pada perubahan nilai harga saham, ROA, ROE, dan PER. Penelitian ini bertujuan mengetahui pengaruh ROA, ROE, PER terhadap harga saham perusahaan farmasi periode 2019-2020. Jenis penelitian ini merupakan studi empiris, metode analisa data yang digunakan adalah dokumentasi dari data sekunder dengan membandingkan instrument rasio keuangan. Teknik analisa data yang digunakan adalah analisa regresi linear berganda. Hasil penelitian menunjukkan Uji t parsial regresi linear berganda Return on Asset (X1) memiliki nilai sig 0,969 > 0,05 maka artinya variabel independen (X) secara parsial tidak berpengaruh terhadap variabel dependen (Y), Return on Equity (X2) memiliki nilai sig 0,675 > 0,05 maka artinya variabel independen (X) secara parsial tidak berpengaruh terhadap variabel dependen (Y), Price Earning Ratio (X3) memiliki nilai sig 0,210 > 0,05 maka artinya variabel independen (X) secara parsial tidak berpengaruh terhadap variabel dependen (Y). kemudian Uji F simultan ROA (X1) memiliki nilai t hitung 0,366 > 0,05 maka artinya variabel independen (X) secara Simultan tidak berpengaruh terhadap variabel dependen (Y), ROE (X2) memiliki nilai t hitung 0,366 > 0,05 maka artinya variabel independen (X) secara Simultan tidak berpengaruh terhadap variabel dependen (Y), PER (X3) memiliki nilai t hitung 0,366 > 0,05 maka artinya variabel independen (X) secara Simultan tidak berpengaruh terhadap variabel dependen (Y). masukan bagi perusahaan farmasi BUMN dan BUMS diharapkan masing-masing dapat meningkatkan ROA, ROE dan PER karena semakin tinggi nilai rasio ini akan menunjukkan semakin tinggi pula laba yang diperoleh sehingga membuat para investor tertarik dalam berinvestasi dan semakin banyak permintaan saham juga dengan sendirinya menyebabkan naiknya harga saham. the phenomenon of fluctuations in profits, total assets and equity each year in state-owned and BUMS pharmaceutical sector companies will have an impact on changes in the value of stock prices, ROA, ROE, and PER. This study aims to determine the effect of ROA, ROE, PER on stock prices of pharmaceutical companies for the 2019-2020 period. This type of research is an empirical study, the data analysis method used is documentation of secondary data by comparing financial ratio instruments. The data analysis technique used is multiple linear regression analysis. The results showed that the partial t-test of multiple linear regression Return on Assets (X1) had a sig value of 0.969 > 0.05, meaning that the independent variable (X) partially had no effect on the dependent variable (Y), Return on Equity (X2) had a sig value. 0.675 > 0.05, it means that the independent variable (X) partially has no effect on the dependent variable (Y), Price Earning Ratio (X3) has a sig value of 0.210 > 0.05, which means that the independent variable (X) partially has no effect on the variable. dependent (Y). then the F-test Simultaneous Return on Assets (X1) has a t-count value of 0.366> 0.05, meaning that the independent variable (X) simultaneously has no effect on the dependent variable (Y), Return on Equity (X2) has a t-count value of 0.366> 0 0.05, it means that the independent variable (X) simultaneously has no effect on the dependent variable (Y), Price Earning Ratio (X3) has a t-count value of 0.366> 0.05, which means that the independent variable (X) simultaneously has no effect on the dependent variable ( Y). input for state-owned pharmaceutical companies and state-owned enterprises is expected to increase ROA, ROE and PER, respectively, because the higher the value of this ratio will indicate the higher the profit earned so that investors are interested in investing and the more demand for shares will automatically increase the price. share.]]>
